BR0211008A - Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante - Google Patents

Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante

Info

Publication number
BR0211008A
BR0211008A BR0211008-3A BR0211008A BR0211008A BR 0211008 A BR0211008 A BR 0211008A BR 0211008 A BR0211008 A BR 0211008A BR 0211008 A BR0211008 A BR 0211008A
Authority
BR
Brazil
Prior art keywords
active ingredient
ingredient combination
substance
addictive
pharmacological therapy
Prior art date
Application number
BR0211008-3A
Other languages
English (en)
Inventor
Joachim Moormann
Klaus Opitz
Hermann Mucke
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of BR0211008A publication Critical patent/BR0211008A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

"COMBINAçãO DE INGREDIENTE ATIVO, USO DE UMA COMBINAçãO DE INGREDIENTE ATIVO E MéTODO PARA A TERAPIA FARMACOLóGICA DE UMA SUBSTâNCIA QUE CAUSA DEPENDêNCIA OU QUE SEJA INTOXICANTE". A presente invenção refere-se a uma combinação de ingrediente ativo composta de pelo menos um modulador do sistema colinérgico com pelo menos uma substância tendo uma atividade antiexcitante para a terapia farmacológica de substâncias que causam a dependência ou que seja intoxicante, em particular de alcoolismo.
BR0211008-3A 2001-06-18 2002-06-15 Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante BR0211008A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
PCT/EP2002/006630 WO2002102388A2 (de) 2001-06-18 2002-06-15 Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus

Publications (1)

Publication Number Publication Date
BR0211008A true BR0211008A (pt) 2004-10-26

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211008-3A BR0211008A (pt) 2001-06-18 2002-06-15 Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante

Country Status (28)

Country Link
US (1) US20040192683A1 (pt)
EP (1) EP1397138B1 (pt)
JP (1) JP2005500298A (pt)
KR (1) KR20040010744A (pt)
CN (1) CN1527711A (pt)
AR (1) AR034493A1 (pt)
AT (1) ATE286397T1 (pt)
AU (1) AU2002323873B2 (pt)
BR (1) BR0211008A (pt)
CA (1) CA2450787C (pt)
CZ (1) CZ299951B6 (pt)
DE (2) DE10129265A1 (pt)
EA (1) EA006647B1 (pt)
ES (1) ES2236551T3 (pt)
HK (1) HK1063292A1 (pt)
HU (1) HUP0400865A3 (pt)
IL (2) IL159345A0 (pt)
MX (1) MXPA03011825A (pt)
MY (1) MY129726A (pt)
NO (1) NO20035458D0 (pt)
NZ (1) NZ529944A (pt)
PL (1) PL367207A1 (pt)
PT (1) PT1397138E (pt)
SK (1) SK287180B6 (pt)
TW (1) TWI325320B (pt)
UA (1) UA76753C2 (pt)
WO (1) WO2002102388A2 (pt)
ZA (1) ZA200309232B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
EP1895995A2 (en) * 2005-05-13 2008-03-12 Alza Corporation Multilayer drug system for the delivery of galantamine
DE602006017719D1 (de) 2005-09-01 2010-12-02 Mitsubishi Chem Corp Verfahren zur wärmebehandlung von polyesterteilchen und verfahren zur mehrstufigen festphasenpolykondensation von polyesterteilchen
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
PL2395990T3 (pl) 2009-02-12 2015-04-30 Univ Indiana Res & Tech Corp Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
EP4349369A3 (en) * 2010-12-03 2024-05-15 Nalpropion Pharmaceuticals LLC Increasing drug bioavailability in naltrexone therapy
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN108210486B (zh) * 2016-12-14 2020-05-19 陆汝斌 组合物用于制备治疗酒瘾或酒精滥用的药物的用途
CN111372578A (zh) 2017-08-24 2020-07-03 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (pt) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CZ295528B6 (cs) * 1994-10-21 2005-08-17 Sanochemia Pharmazeutika Ag Způsob výroby derivátů 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinu
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6784202B1 (en) * 1998-04-17 2004-08-31 Prescient Neuropharma Inc. Cubane derivatives as metabotropic glutamate receptor agonists or antagonists and process for their preparation
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit

Also Published As

Publication number Publication date
CZ20033390A3 (en) 2004-03-17
MY129726A (en) 2007-04-30
UA76753C2 (uk) 2006-09-15
ZA200309232B (en) 2004-07-21
HUP0400865A3 (en) 2011-03-28
DE10129265A1 (de) 2003-01-02
EA006647B1 (ru) 2006-02-24
EP1397138A2 (de) 2004-03-17
ES2236551T3 (es) 2005-07-16
HUP0400865A2 (hu) 2004-07-28
MXPA03011825A (es) 2005-03-07
EP1397138B1 (de) 2005-01-05
WO2002102388A3 (de) 2003-09-18
WO2002102388A2 (de) 2002-12-27
AR034493A1 (es) 2004-02-25
PT1397138E (pt) 2005-04-29
SK287180B6 (sk) 2010-02-08
KR20040010744A (ko) 2004-01-31
CA2450787C (en) 2009-06-02
US20040192683A1 (en) 2004-09-30
AU2002323873B2 (en) 2006-11-16
JP2005500298A (ja) 2005-01-06
ATE286397T1 (de) 2005-01-15
EA200400041A1 (ru) 2004-04-29
CZ299951B6 (cs) 2009-01-07
NZ529944A (en) 2007-02-23
TWI325320B (en) 2010-06-01
HK1063292A1 (en) 2004-12-24
IL159345A0 (en) 2004-06-01
PL367207A1 (en) 2005-02-21
NO20035458D0 (no) 2003-12-08
SK15652003A3 (sk) 2004-04-06
IL159345A (en) 2009-02-11
DE50201958D1 (de) 2005-02-10
CN1527711A (zh) 2004-09-08
CA2450787A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
BR0211008A (pt) Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante
HUP9701560A1 (hu) "Olaj a vízben"típusú topikális alkalmazású folyékony emulzió készítmény
BR9713734A (pt) Derivados de sulfonamidas, processo para sua preparação, e seu uso como medicamentos
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
BR9703624A (pt) Combinação formulação farmacêutica processo para o tratamento de depressão em um animal uso de mirtazapina uso de um ou mais srri's e embalagem
PT1010688E (pt) 2-fenil-1-(3,4-di-hidroxi-5-nitrofenil)-1-etanonas substituidas seu uso no tratamento de algumas perturbacoes do sistema nervoso central e periferico e formulacoes do sistema nervoso central e periferico e formulacoes farmaceuticas que as contem
ES2081936T3 (es) Composiciones anfoteras y formas polimericas de alfa-hidroxiacidos, y su uso terapeutico.
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
BR0213589A (pt) Formas de dosagens de liberação modificada
BG103552A (en) Therapeutical forms
ES2171498T3 (es) Composicion farmaceutica solida que comprende un excipiente capaz de juntarse con el agua.
BR9909636A (pt) Processo para a preparação de uma formulação, e, formulação
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
FI963221A (fi) 6-substituoitu mykofenolihappo ja sen johdannaiset, joilla on immunosuppressiivista aktiivisuutta
BR9808895A (pt) Partìcula de detergente
ES2176459T3 (es) Patrones y soluciones de contraste estabilizados.
BR9811003A (pt) processo para a prevenção ou tratamento de prurido em um paciente mamìfero
ES2059869T3 (es) Preparado farmaceutico que contiene piroxicam para uso topico.
ATE131031T1 (de) Zubereitung zur topischen anwendung.
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
ES2179375T3 (es) Composiciones farmaceuticas estabilizadas, a base de quinupristina y de dalfopristina y su preparacion.
ES2189886T3 (es) Composicion farmaceutica para aplicacion topica.
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
ATE211383T1 (de) Topische aciclovir-zubereitung
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.